TOP - July 2021 Vol 14, No 4

Lung cancer remains the leading cause of cancer death worldwide, but the treatment landscape is rapidly evolving.
The recent approval of several new HER2-targeted therapies has led to significant advances in the treatment of patients with HER2-positive metastatic breast cancer.
Although standard chemotherapy is often effective in the first-line treatment of locally invasive urothelial carcinoma, until recently, there have been few second- or third-line treatment options for patients with advanced or metastatic disease.
According to the American Cancer Society, nearly 35,000 new cases of multiple myeloma will be diagnosed in the United States in 2021, and approximately 12,410 deaths will be attributed to the disease.1 However, with the introduction of several novel therapies, the outcomes for patients with newly diagnosed multiple myeloma have improved significantly over the past decade.
The COVID-19 pandemic caused significant disruptions to virtually all aspects of oncology care.
Page 2 of 2
Results 11 - 15 of 15